Aberdare ventures ii lp - see footnote investment history in Anacor pharmaceuticals inc

Filed on 2010-12-01 by Aberdare Ii Annex Fund L P SEC CIK 1352036 Form 4

Accession 0001104659-10-060757.txt Sec File: edgar/data/1352036/0001104659-10-060757-index.htm

2010-11-30 Aberdare Ventures Ii Lp (CIK 1418079) through See Footnote

Invested in Anacor Pharmaceuticals Inc sold 99645 shares at $0 remaining shares owned 0

Series E Preferred Stock Anacor Pharmaceuticals Inc Anac underlying security shares 99645 underlying security title Common Stock

f7 consists of 99,645 shares held by aberdare ii annex fund, l.p. ("aberdare annex"). aberdare gp ii serves as the sole general partner of aberdare annex, and has sole voting and investment control over the shares owned by aberdare annex, and may be deemed to own beneficially the shares held by aberdare annex. aberdare gp ii however owns no securities of the issuer directly. klingenstein is the manager of aberdare gp ii and has voting and dispositive power over the shares held by aberdare annex. klingenstein disclaims beneficial ownership of the reportable securities, except to the extent of his pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.
f1 the series a-1 preferred stock, series c preferred stock, series d preferred stock and series e preferred stock converted into common stock on a 1-for-1 basis and had no expiration date.


Filed on 2010-12-01 by Aberdare Ii Annex Fund L P SEC CIK 1352036 Form 4

Accession 0001104659-10-060757.txt Sec File: edgar/data/1352036/0001104659-10-060757-index.htm

2010-11-30 Aberdare Ventures Ii Lp (CIK 1418079) through See Footnote

Invested in Anacor Pharmaceuticals Inc sold 95788 shares at $0 remaining shares owned 0

Series D Preferred Stock Anacor Pharmaceuticals Inc Anac underlying security shares 95788 underlying security title Common Stock

f6 consists of 2,123 shares held by aberdare bermuda and 93,665 shares held be aberdare ii. aberdare gp ii serves as the sole general partner of aberdare bermuda and aberdare ii, and has sole voting and investment control over the shares owned by aberdare bermuda and aberdare ii, and may be deemed to own beneficially the shares held by aberdare bermuda and aberdare ii. aberdare gp ii however owns no securities of the issuer directly. klingenstein is the manager of aberdare gp ii and has voting and dispositive power over the shares held by aberdare bermuda and aberdare ii. klingenstein disclaims beneficial ownership of the reportable securities, except to the extent of his pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.
f1 the series a-1 preferred stock, series c preferred stock, series d preferred stock and series e preferred stock converted into common stock on a 1-for-1 basis and had no expiration date.


Filed on 2010-12-01 by Aberdare Ii Annex Fund L P SEC CIK 1352036 Form 4

Accession 0001104659-10-060757.txt Sec File: edgar/data/1352036/0001104659-10-060757-index.htm

2010-11-30 Aberdare Ventures Ii Lp (CIK 1418079) through See Footnote

Invested in Anacor Pharmaceuticals Inc sold 593697 shares at $0 remaining shares owned 0

Series C Preferred Stock Anacor Pharmaceuticals Inc Anac underlying security shares 593697 underlying security title Common Stock

f5 consists of 13,160 shares held by aberdare bermuda and 580,537 shares held be aberdare ii. aberdare gp ii serves as the sole general partner of aberdare bermuda and aberdare ii, and has sole voting and investment control over the shares owned by aberdare bermuda and aberdare ii, and may be deemed to own beneficially the shares held by aberdare bermuda and aberdare ii. aberdare gp ii however owns no securities of the issuer directly. klingenstein is the manager of aberdare gp ii and has voting and dispositive power over the shares held by aberdare bermuda and aberdare ii. klingenstein disclaims beneficial ownership of the reportable securities, except to the extent of his pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.
f1 the series a-1 preferred stock, series c preferred stock, series d preferred stock and series e preferred stock converted into common stock on a 1-for-1 basis and had no expiration date.


Filed on 2010-12-01 by Aberdare Ii Annex Fund L P SEC CIK 1352036 Form 4

Accession 0001104659-10-060757.txt Sec File: edgar/data/1352036/0001104659-10-060757-index.htm

2010-11-30 Aberdare Ventures Ii Lp (CIK 1418079) through See Footnote

Invested in Anacor Pharmaceuticals Inc sold 256651 shares at $0 remaining shares owned 0

Series B Preferred Stock Anacor Pharmaceuticals Inc Anac underlying security shares 337831 underlying security title Common Stock

f4 consists of 7,488 shares held by aberdare bermuda. and 330,343 shares held be aberdare ii. aberdare gp ii serves as the sole general partner of aberdare bermuda and aberdare ii, and has sole voting and investment control over the shares owned by aberdare bermuda and aberdare ii, and may be deemed to own beneficially the shares held by aberdare bermuda and aberdare ii. aberdare gp ii however owns no securities of the issuer directly. klingenstein is the manager of aberdare gp ii and has voting and dispositive power over the shares held by aberdare bermuda and aberdare ii. klingenstein disclaims beneficial ownership of the reportable securities, except to the extent of his pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.
f2 the series b preferred stock converted into common stock on the basis of 1.316 shares of common stock for one share of series b preferred stock and had no expiration date.


Filed on 2010-12-01 by Aberdare Ii Annex Fund L P SEC CIK 1352036 Form 4

Accession 0001104659-10-060757.txt Sec File: edgar/data/1352036/0001104659-10-060757-index.htm

2010-11-30 Aberdare Ventures Ii Lp (CIK 1418079) through See Footnote

Invested in Anacor Pharmaceuticals Inc sold 324975 shares at $0 remaining shares owned 0

Series A-1 Preferred Stock Anacor Pharmaceuticals Inc Anac underlying security shares 324975 underlying security title Common Stock

f3 consists of 7,203 shares held by aberdare ventures ii, l.p. ("aberdare bermuda") and 317,772 shares held be aberdare ventures ii, l.p. ("aberdare ii"). aberdare gp ii, l.l.c. ("aberdare gp ii") serves as the sole general partner of aberdare bermuda and aberdare ii, and has sole voting and investment control over the shares owned by aberdare bermuda and aberdare ii, and may be deemed to own beneficially the shares held by aberdare bermuda and aberdare ii. aberdare gp ii however owns no securities of the issuer directly. paul h. klingenstein ("klingenstein") is the manager of aberdare gp ii and has voting and dispositive power over the shares held by aberdare bermuda and aberdare ii. klingenstein disclaims beneficial ownership of the reportable securities, except to the extent of his pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.
f1 the series a-1 preferred stock, series c preferred stock, series d preferred stock and series e preferred stock converted into common stock on a 1-for-1 basis and had no expiration date.


Filed on 2010-12-01 by Aberdare Ii Annex Fund L P SEC CIK 1352036 Form 4

Accession 0001104659-10-060757.txt Sec File: edgar/data/1352036/0001104659-10-060757-index.htm

2010-11-30 Aberdare Ventures Ii Lp (CIK 1418079) through See Footnote

Invested in Anacor Pharmaceuticals Inc bought 300000 shares at $5.00 remaining shares owned 1751936

Common Stock Anacor Pharmaceuticals Inc Anac Transaction code: P Open market or private purchase of securities

f8 consists of 300,000 shares held by aberdare annex. aberdare gp ii serves as the sole general partner of aberdare annex, and has sole voting and investment control over the shares owned by aberdare annex, and may be deemed to own beneficially the shares held by aberdare annex. aberdare gp ii however owns no securities of the issuer directly. klingenstein is the manager of aberdare gp ii and has voting and dispositive power over the shares held by aberdare annex. klingenstein disclaims beneficial ownership of the reportable securities, except to the extent of his pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.


Filed on 2010-12-01 by Aberdare Ii Annex Fund L P SEC CIK 1352036 Form 4

Accession 0001104659-10-060757.txt Sec File: edgar/data/1352036/0001104659-10-060757-index.htm

2010-11-30 Aberdare Ventures Ii Lp (CIK 1418079) through See Footnote

Invested in Anacor Pharmaceuticals Inc bought 99645 shares remaining shares owned 1451936

Common Stock Anacor Pharmaceuticals Inc Anac Transaction code: C Conversion of derivative security (usually options)

f1 the series a-1 preferred stock, series c preferred stock, series d preferred stock and series e preferred stock converted into common stock on a 1-for-1 basis and had no expiration date.
f7 consists of 99,645 shares held by aberdare ii annex fund, l.p. ("aberdare annex"). aberdare gp ii serves as the sole general partner of aberdare annex, and has sole voting and investment control over the shares owned by aberdare annex, and may be deemed to own beneficially the shares held by aberdare annex. aberdare gp ii however owns no securities of the issuer directly. klingenstein is the manager of aberdare gp ii and has voting and dispositive power over the shares held by aberdare annex. klingenstein disclaims beneficial ownership of the reportable securities, except to the extent of his pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.


Filed on 2010-12-01 by Aberdare Ii Annex Fund L P SEC CIK 1352036 Form 4

Accession 0001104659-10-060757.txt Sec File: edgar/data/1352036/0001104659-10-060757-index.htm

2010-11-30 Aberdare Ventures Ii Lp (CIK 1418079) through See Footnote

Invested in Anacor Pharmaceuticals Inc bought 95788 shares remaining shares owned 1352291

Common Stock Anacor Pharmaceuticals Inc Anac Transaction code: C Conversion of derivative security (usually options)

f1 the series a-1 preferred stock, series c preferred stock, series d preferred stock and series e preferred stock converted into common stock on a 1-for-1 basis and had no expiration date.
f6 consists of 2,123 shares held by aberdare bermuda and 93,665 shares held be aberdare ii. aberdare gp ii serves as the sole general partner of aberdare bermuda and aberdare ii, and has sole voting and investment control over the shares owned by aberdare bermuda and aberdare ii, and may be deemed to own beneficially the shares held by aberdare bermuda and aberdare ii. aberdare gp ii however owns no securities of the issuer directly. klingenstein is the manager of aberdare gp ii and has voting and dispositive power over the shares held by aberdare bermuda and aberdare ii. klingenstein disclaims beneficial ownership of the reportable securities, except to the extent of his pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.


Filed on 2010-12-01 by Aberdare Ii Annex Fund L P SEC CIK 1352036 Form 4

Accession 0001104659-10-060757.txt Sec File: edgar/data/1352036/0001104659-10-060757-index.htm

2010-11-30 Aberdare Ventures Ii Lp (CIK 1418079) through See Footnote

Invested in Anacor Pharmaceuticals Inc bought 593697 shares remaining shares owned 1256503

Common Stock Anacor Pharmaceuticals Inc Anac Transaction code: C Conversion of derivative security (usually options)

f1 the series a-1 preferred stock, series c preferred stock, series d preferred stock and series e preferred stock converted into common stock on a 1-for-1 basis and had no expiration date.
f5 consists of 13,160 shares held by aberdare bermuda and 580,537 shares held be aberdare ii. aberdare gp ii serves as the sole general partner of aberdare bermuda and aberdare ii, and has sole voting and investment control over the shares owned by aberdare bermuda and aberdare ii, and may be deemed to own beneficially the shares held by aberdare bermuda and aberdare ii. aberdare gp ii however owns no securities of the issuer directly. klingenstein is the manager of aberdare gp ii and has voting and dispositive power over the shares held by aberdare bermuda and aberdare ii. klingenstein disclaims beneficial ownership of the reportable securities, except to the extent of his pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.


Filed on 2010-12-01 by Aberdare Ii Annex Fund L P SEC CIK 1352036 Form 4

Accession 0001104659-10-060757.txt Sec File: edgar/data/1352036/0001104659-10-060757-index.htm

2010-11-30 Aberdare Ventures Ii Lp (CIK 1418079) through See Footnote

Invested in Anacor Pharmaceuticals Inc bought 337831 shares remaining shares owned 662806

Common Stock Anacor Pharmaceuticals Inc Anac Transaction code: C Conversion of derivative security (usually options)

f2 the series b preferred stock converted into common stock on the basis of 1.316 shares of common stock for one share of series b preferred stock and had no expiration date.
f4 consists of 7,488 shares held by aberdare bermuda. and 330,343 shares held be aberdare ii. aberdare gp ii serves as the sole general partner of aberdare bermuda and aberdare ii, and has sole voting and investment control over the shares owned by aberdare bermuda and aberdare ii, and may be deemed to own beneficially the shares held by aberdare bermuda and aberdare ii. aberdare gp ii however owns no securities of the issuer directly. klingenstein is the manager of aberdare gp ii and has voting and dispositive power over the shares held by aberdare bermuda and aberdare ii. klingenstein disclaims beneficial ownership of the reportable securities, except to the extent of his pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.


Filed on 2010-12-01 by Aberdare Ii Annex Fund L P SEC CIK 1352036 Form 4

Accession 0001104659-10-060757.txt Sec File: edgar/data/1352036/0001104659-10-060757-index.htm

2010-11-30 Aberdare Ventures Ii Lp (CIK 1418079) through See Footnote

Invested in Anacor Pharmaceuticals Inc bought 324975 shares remaining shares owned 324975

Common Stock Anacor Pharmaceuticals Inc Anac Transaction code: C Conversion of derivative security (usually options)

f1 the series a-1 preferred stock, series c preferred stock, series d preferred stock and series e preferred stock converted into common stock on a 1-for-1 basis and had no expiration date.
f3 consists of 7,203 shares held by aberdare ventures ii, l.p. ("aberdare bermuda") and 317,772 shares held be aberdare ventures ii, l.p. ("aberdare ii"). aberdare gp ii, l.l.c. ("aberdare gp ii") serves as the sole general partner of aberdare bermuda and aberdare ii, and has sole voting and investment control over the shares owned by aberdare bermuda and aberdare ii, and may be deemed to own beneficially the shares held by aberdare bermuda and aberdare ii. aberdare gp ii however owns no securities of the issuer directly. paul h. klingenstein ("klingenstein") is the manager of aberdare gp ii and has voting and dispositive power over the shares held by aberdare bermuda and aberdare ii. klingenstein disclaims beneficial ownership of the reportable securities, except to the extent of his pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.